HomeTagsQuanterix Corporation

Quanterix Corporation

Biotechnology

Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

News Desk - August 1, 2023

The company’s ultra-sensitive biomarker technology supports milestone achievement in establishing a method for clinicians to identify and interpret elevated values of sNfL in children...

Healthcare

FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials

Business Wire - April 28, 2023

Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, announced that blood-based NfL measurements provided compelling support for the...